European equities traded in the US as American depositary receipts were slightly lower late Thursday morning, declining 0.12% to 1,510.10 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Genfit (GNFT) and financial services company Banco Bilbao Vizcaya Argentaria (BBVA), which rose 2.6% and 1.8%, respectively. They were followed by accommodations booking company trivago (TRVG) and financial services company Banco Santander (SAN), which were up 0.6% each.
The decliners from continental Europe were led by biotech firm Evaxion (EVAX) and semiconductor company Sequans Communications (SQNS), which fell 9.2% and 3.9%, respectively. They were followed by 3D printer company Materialise (MTLS) and internet browser company Opera (OPRA), which were down 2.6% and 2.4%, respectively.
From the UK and Ireland, the gainers were led by biotech firm Trinity Biotech (TRIB), which soared 203%, followed by fellow biotech firm Autolus Therapeutics (AUTL), which advanced 4.1%. Biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) Amarin (AMRN) increased 2% and 0.7%, respectively.
And the decliners from the UK and Ireland were led by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and NuCana (NCNA), which dropped 11% and 6.4%, respectively. They were followed by biopharmaceutical company Mereo BioPharma Group (MREO) and pharmaceutical company Silence Therapeutics (SLN), which lost 3.8% and 2.4%, respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.